Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REL-1017 Adjunctive Treatment in Major Depressive Disorder (SM-1)
2023-507399-27-00Phase 3Completed
- Sponsor
- MGGM LLC
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing REL-1017 + ongoing antidepressant therapy with Placebo + ongoing antidepressant therapy (2 arms). Primary endpoint: Change in MADRS10 total score from baseline to Day 28. Started Dec 2024; status: completed.
02
Drugs
esmethadone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2023-507399-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507399-27-00.